MarketMoodz
BIIB — Biogen Inc.
Is BIIB overbought or oversold? Here is the current MarketMoodz read.
Biogen Inc. (BIIB) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $216.12. The rating moved from Neutral to Overbought on July 2, 2026 and has changed 27 times in the last 90 days.
- Public ratingOverbought (as of July 5, 2026)
- Last close$216.12
- Rating changesRating changed 27 times in the last 90 days
- Last changeMoved from Neutral to Overbought on July 2, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
Latest MarketMoodz coverage
- Rep. Maria Elvira Salazar Resumes Tech, Biotech Trades2026-06-11
- Biogen Advances Tau Drug Diranersen to Phase 3 Despite Mixed Data2026-05-14
- Biogen stock gains as FDA extends Leqembi review to Aug. 24, 20262026-05-08
- Wells Fargo backs Biogen pivot to immunology and kidney disease, lifts price target to $2502026-04-20
- Monday analyst calls hit Nvidia, Apple, Microsoft, Amazon ahead of earnings2026-04-20
See today's live rating, score and targets
Members see the live hourly rating for BIIB — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.